)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aurobindo Pharma
Aurobindo Pharma (AUROPHARMA) investor relations material
Aurobindo Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary6 Aug, 2026
Executive summary
Consolidated revenues rose 16.3% year-over-year to INR 9,150 crore (91,503.5 million), driven by broad-based growth across all business areas and strong US performance from volume gains and new launches.
Operating EBITDA reached INR 1,924 crore (margin 21.0%), up 20% year-over-year, excluding a one-time lease receivable derecognition impact.
Net profit after tax rose to INR 1,032 crore (10,320.3 million), a 25.2% increase year-over-year, with EPS at 17.86, up from 14.20.
Lannett acquisition completed, strengthening the U.S. platform and expanding presence in complex and controlled substances.
Free cash flow of $98 million generated, maintaining a net cash position of $42 million after major acquisition and buyback outflows.
Financial highlights
Revenue from operations grew 16.3% year-over-year to INR 9,150 crore; gross profit increased 19.3% to INR 5,523 crore.
Gross margin improved to 60.4% (up 153 bps year-over-year); operating EBITDA margin rose to 21.0%.
Net profit attributable to owners was INR 1,033 crore, up 25.2% year-over-year; reported EPS increased to 17.86.
U.S. revenue increased 8.1% year-over-year to INR 3,770 crore; 10 new products launched, 9 ANDAs filed, 10 final approvals received.
European revenues reached EUR 267 million, up 11% year-over-year in constant currency; Growth markets revenue surged 38% year-over-year to INR 1,063 crore.
Outlook and guidance
FY 2027 guidance reiterated: double-digit revenue growth, EBITDA margin above 21%, and absolute EBITDA exceeding INR 8,000 crore.
Strategic focus on high-value businesses, complex generics, specialty pharmaceuticals, injectables, biologics, and CDMO services.
R&D expenses expected to remain at 4% of revenue, with a slight decrease in development costs as clinical studies conclude.
Strategic investments in manufacturing capacity and pipeline to sustain growth into 2030.
Biosimilars and biologics contract manufacturing expansion underway, with new filings and commercial launches planned in major markets.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aurobindo Pharma
- Revenue rose 15.3% as formulations surged and debt fell amid major capacity expansion.AUROPHARMA
Q4 09/10 - Record revenue, margin growth, and global expansion with strong biosimilars and CDMO momentum.AUROPHARMAQ4 25/26
- Q3FY26 revenue rose 8.4% YoY, with strong Europe growth, robust margins, and strategic investments.AUROPHARMAQ3 25/26
- Q2 FY2026 revenue rose 6.3% YoY, EBITDA margin at 20.3%, with strong US, Europe, and biosimilars growth.AUROPHARMAQ2 25/26
- Revenue up 4% YoY, net profit down 10%, biosimilars pipeline and cash position strengthened.AUROPHARMAQ1 25/26
- Q2 FY25 saw 8% revenue growth, margin gains, and strategic progress in biosimilars and CMO.AUROPHARMAQ2 24/25
- Q1 FY25 delivered strong revenue and profit growth, margin expansion, and major buyback approval.AUROPHARMAQ1 24/25
- Record FY25 revenue, profit, and cash flow, with strong US/Europe growth and biosimilar progress.AUROPHARMAQ4 24/25
- Record revenue, margin expansion, acquisitions, and biosimilar launches drive growth.AUROPHARMAQ3 24/25
Next Aurobindo Pharma earnings date
Q2 26/275 Nov, 2026
Aurobindo Pharma
Next Aurobindo Pharma earnings date
Q2 26/275 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aurobindo Pharma Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of generic medicines. The company’s product portfolio includes antibiotics, antiretrovirals, cardiovascular drugs, central nervous system agents, gastroenterology products, and anti-allergics, among others. Aurobindo Pharma serves markets globally, supplying generic pharmaceuticals to hospitals, pharmacies, and healthcare providers. The company also produces active pharmaceutical ingredients (APIs) and has expanded into specialty drugs and biosimilars. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.